SRRA实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (1 Jan 1970 @ 08:00):

Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs...

Stats
今日成交量	0.00
平均成交量	651 457
市值	0.00
EPS	$0 ( 2022-08-04 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.34
ATR14	$0.324 (0.59%)

Insider Trading

Date	Person	Action	Amount	type
2022-07-01	Vivo Opportunity, Llc	Sell	431 947	Common Stock
2022-07-01	Vivo Opportunity, Llc	Sell	75 749	Series A Warrants
2022-07-01	Orbimed Advisors Llc	Sell	226 704	Common Stock
2022-07-01	Orbimed Advisors Llc	Sell	170 437	Series A Warrants
2022-07-01	Ashiya Mona	Sell	226 704	Common Stock

INSIDER POWER
-97.17
Last 99 transactions
Buy: 4 604 902 \| Sell: 10 646 034

音量相关性

長: 0.15 (neutral)

短: -0.71 (moderate negative)

Signal:(77.923) Neutral

Sierra Oncology Inc 相关性

10 最正相关
TA	0.981
IIN	0.98
ECHO	0.98
MLVF	0.979
SIOX	0.972
ATCX	0.971
KRTX	0.969
MOR	0.968
EXFO	0.965
CRTO	0.963

10 最负相关
BIOL	-0.972
MRBK	-0.971
WTER	-0.971
CYXT	-0.971
PIII	-0.966
UTME	-0.965
BCAB	-0.963
SMFL	-0.961
UTMD	-0.958
RVSB	-0.957

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Sierra Oncology Inc 相关性 - 货币/商品

0.48
( neutral )

0.75
( moderate )

-0.14
( neutral )

0.32
( neutral )

0.60
( weak )

-0.68
( moderate negative )

Sierra Oncology Inc 财务报表

Annual	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-7.14

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-7.14

FY	2020
营收:	$300 000
毛利润:	$0.00 (0.00 %)
EPS:	$-7.70

FY	2019
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-30.30

Financial Reports:

No articles found.

Sierra Oncology Inc

Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California. As of July 1, 2022, Sierra Oncology, Inc. operates as a subsidiary of GSK plc.